|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.850 USD | -2.32% |
|
-5.09% | -67.41% |
| 07-08 | Seres Therapeutics Announces Early Clinical Data Showing Potential For SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis | CI |
| 07-08 | Seres Therapeutics, Inc. - Special Call |
Company Valuation: Seres Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 765.1 | 697.7 | 181 | 141.9 | 134.6 | 46.97 | - | - |
| Change | - | -8.81% | -74.06% | -21.59% | -5.12% | -65.11% | - | - |
| Enterprise Value (EV) | 634.3 | 697.3 | 266.9 | 202.7 | 134.6 | 46.97 | 46.97 | 46.97 |
| Change | - | 9.93% | -61.72% | -24.05% | -33.6% | -65.11% | 0% | 0% |
| P/E | -11.6x | -2.42x | -1.57x | - | 23.3x | -0.65x | -0.74x | -0.67x |
| PBR | - | - | -4.21x | 10.4x | - | - | - | - |
| PEG | - | -0x | 0x | - | - | 0x | 0.1x | -0.07x |
| Capitalization / Revenue | 5.28x | 97.9x | 1.43x | - | 171x | 3.65x | 131x | 131x |
| EV / Revenue | 0x | 0x | 0x | - | 0x | 3.65x | 131x | 131x |
| EV / EBITDA | -0x | -0x | -0x | -0x | - | -0.64x | -0.44x | -0.4x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.6x | -0.47x | -0.42x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -14.4 | -46.2 | -17.8 | - | 0.64 | -7.515 | -6.575 | -7.22 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 144.9 | 7.128 | 126.3 | - | 0.789 | 12.86 | 0.358 | 0.358 |
| EBITDA 1 | -58.55 | -239.9 | -96.14 | -115.8 | - | -73 | -107.8 | -118.6 |
| EBIT 1 | -64.49 | -246.5 | -102.4 | -121.3 | -93.97 | -78.2 | -100.5 | -111.5 |
| Net income 1 | -65.58 | -250.2 | -113.7 | 0.136 | 5.696 | -70.97 | -99.82 | -110.8 |
| Net Debt | -130.8 | -0.44 | 85.97 | 60.85 | - | - | - | - |
| Reference price 2 | 166.600 | 112.000 | 28.000 | 16.620 | 14.880 | 4.850 | 4.850 | 4.850 |
| Nbr of stocks (in thousands) | 4,592 | 6,230 | 6,463 | 8,537 | 9,047 | 9,684 | - | - |
| Announcement Date | 3/1/22 | 3/7/23 | 3/5/24 | 3/13/25 | 3/12/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.65x | - | - | - | 46.97M | |
| 33.11x | 8.21x | 25.31x | 0.04% | 56.19B | |
| 20.62x | 6.35x | 13.89x | 1.54% | 54.83B | |
| -41x | 13.02x | -38.35x | -.--% | 22.7B | |
| -18.25x | 4.33x | -7.59x | -.--% | 23.04B | |
| 25.46x | 4.98x | 13.19x | -.--% | 20.23B | |
| 24.92x | 4.83x | 15.71x | -.--% | 17.83B | |
| -786.44x | 37.38x | -4208.26x | -.--% | 15.65B | |
| 45.88x | 18.59x | 47.88x | 0.08% | 15.24B | |
| 17.56x | 5.09x | 11.87x | -.--% | 14.03B | |
| Average | -67.88x | 11.42x | -458.48x | 0.19% | 23.98B | |
| Weighted average by Cap. | -36.55x | 9.73x | -263.99x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- MCRB Stock
- Valuation Seres Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
